[1] Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma[J]. Eur Urol, 2019, 75(1): 74-84.
[2] Ljungberg B, Campbell CS, Choi HY, et al. The epidemiology of renal cell carcinoma[J]. Eur Urol, 2011, 60(4): 615-621.
[3] Navai N, Wood GC. Environmental and modifiable risk factors in renal cell carcinoma[J]. Urol Oncol Semin Orig Investig, 2012, 30(2): 220-224.
[4] Bleumer I. Immunotherapy for renal cell carcinoma[J]. Eur Urol,2003, 44(1): 65-75.
[5] 储昭阳, 朱向明, 江峰, 等. PPARGC1A通过影响肿瘤微环境中免疫成分改善肾透明细胞癌的预后[J]. 右江民族医学院学报, 2020, 42(6): 716-722.
[6] Kroemer G, Mariño G, Levine B. Autophagy and the integrated stress response[J].Mol Cell, 2010, 40(2): 280-293.
[7] White E. The role for autophagy in cancer[J]. J Clin Invest, 2015, 125(1): 42-46.
[8] Tan Q, Wang M, Yu M, et al. Role of autophagy as a survival mechanism for hypoxic cells in tumors[J]. Neoplasia, 2016, 18(6): 347-355.
[9] White E, Dipaola RS. The double-edged sword of autophagy modulation in cancer[J]. Clin Cancer Res, 2009, 15(17): 5308-5316.
[10] Lotze MT, Maranchie J, Appleman L. Inhibiting autophagy: a novel approach for the treatment of renal cell carcinoma[J]. Cancer J, 2013, 19(4): 341-347.
[11] Cao Q, Bai P. Role of autophagy in renal cancer[J]. J Cancer,2019, 10(11): 2501-2509.
[12] Stockwell BR, Angeli FJP, Bayir H, et al. Ferroptosis: a regulated cell death Nexus linking metabolism, redox biology, and disease[J]. Cell,2017, 171(2): 273-285.
[13] Bebber CM, Müller F, Prieto Clemente L, et al. Ferroptosis in cancer cell biology[J]. Cancers, 2020, 12(1): 164.
[14] Yu HT, Guo PY, Xie XZ, et al. Ferroptosis,a new form of cell death, and its relationships with tumourous diseases[J]. J Cell Mol Med, 2017, 21(4): 648-657.
[15] Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking[J]. Bioinformatics, 2010,26(12): 1572-1573.
[16] Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles[J]. Nat Methods, 2015, 12(5): 453-457.
[17] Chen CX, Gao H, Su XL. Autophagy-related signaling pathways are involved in cancer(Review)[J]. Exp Ther Med, 2021, 22: 710.
[18] Jones TM, Carew JS, Nawrocki ST. Therapeutic targeting of autophagy for renal cell carcinoma therapy[J]. Cancers, 2020, 12(5): 1185.
[19] Li HY, Jin XF, Zhang Z, et al. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells[J]. Cell Biochem Funct, 2013, 31(5): 427-433.
[20] Shen ZY, Song JB, Yung BC, et al. Emerging strategies of cancer therapy based on ferroptosis[J]. Adv Mater, 2018, 30(12): 1704007.
[21] Xu T, Ding W, Ji XY, et al. Molecular mechanisms of ferroptosis and its role in cancer therapy[J]. J Cell Mol Med, 2019, 23(8): 4900-4912.
[22] Yang WH, Ding CKC, Sun TA, et al. The hippo pathway effector TAZ regulates ferroptosis in renal cell carcinoma[J]. Cell Rep, 2019, 28(10): 2501-2508.e4.
[23] Zhou YL, Shen Y, Chen C, et al. The crosstalk between autophagy and ferroptosis: what can we learn to target drug resistance in cancer?[J]. Cancer Biol Med, 2019, 16(4): 630-646.
[24] Gao W, Lam JW, Li JZ, et al. microRNA-138-5p controls sensitivity of nasopharyngeal carcinoma to radiation by targeting EIF4EBP1[J]. Oncol Rep, 2017, 37(2): 913-920.
[25] Wan P, Chen Z, Zhong W, et al. BRDT is a novel regulator of eIF4EBP1 in renal cell carcinoma[J]. Oncol Rep, 2020, 44(6): 2475-2486.
[26] Rashid HO, Yadav RK, Kim HR, et al. ER stress: autophagy induction, inhibition and selection[J]. Autophagy, 2015, 11(11): 1956-1977.
[27] Song SL, Tan J, Miao YY, et al. Crosstalk of autophagy and apoptosis: involvement of the dual role of autophagy under ER stress[J]. J Cell Physiol, 2017, 232(11): 2977-2984.
[28] Zhang J, Ney PA. Role of BNIP3 and NIX in cell death, autophagy, and mitophagy[J]. Cell Death Differ, 2009, 16(7): 939-946.
[29] Lin TY, Chan HH, Chen SH, et al. BIRC5/Survivin is a novel ATG12-ATG5 conjugate interactor and an autophagy-induced DNA damage suppressor in human cancer and mouse embryonic fibroblast cells[J]. Autophagy, 2020, 16(7): 1296-1313.
[30] Zhang HM, Li W, Gu WY, et al. MALAT1 accelerates the development and progression of renal cell carcinoma by decreasing the expression of miR-203 and promoting the expression of BIRC5[J]. Cell Prolif, 2019, 52(5): e12640.
[31] Li D, Liu SW, Xu J, et al. Ferroptosis-related gene CHAC1 is a valid indicator for the poor prognosis of kidney renal clear cell carcinoma[J]. J Cell Mol Med, 2021, 25(7): 3610-3621.
[32] De Santi M, Baldelli G, Diotallevi A, et al. Metformin prevents cell tumorigenesis through autophagy-related cell death[J]. Sci Rep, 2019, 9(1): 66.
[33] Stockwell BR, Jiang X. A physiological function for ferroptosis in tumor suppression by the immune system[J]. Cell Metab, 2019, 30(1): 14-15.
[34] Zhong ZY, Sanchez-Lopez E, Karin M. Autophagy, inflammation, and immunity: a troika governing cancer and its treatment[J]. Cell, 2016, 166(2): 288-298.
[35] Toma M, Wehner R, KloΒβ A, et al. Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis[J]. Oncoimmunology, 2015, 4(6): e1008342.
[36] Dannenmann SR, Thielicke J, Stöckli M, et al. Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma[J]. OncoImmunology, 2013, 2(3): e23562.
[37] Liu TJ, Xia Q, Zhang HB, et al. CCL5-dependent mast cell infiltration into the tumor microenvironment in clear cell renal cell carcinoma patients[J]. Aging, 2020, 12(21): 21809-21836.
[38] Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity[J]. Int J Cancer, 2010, 127(4): 759-767.
[39] Slamanig SA, Nolte MA. The bone marrow as sanctuary for plasma cells and memory T-cells: implications for adaptive immunity and vaccinology[J]. Cells, 2021, 10(6): 1508.
[40] Qi Y, Xia Y, Lin ZY, et al. Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients[J]. Cancer Immunol Immunother, 2020, 69(8): 1565-1576.
[41] Ghatalia P, Gordetsky J, Bae S, et al. Association of a combined panel of tumor infiltrating lymphocytes, plasma cells,and macrophages with recurrence of localized clear cell (cc) renal cell carcinoma (RCC) undergoing surgery[J]. J Clin Oncol, 2016, 34(2_suppl): 502.
